Prevention of Post-operative Pneumonia (POPP)

Study summary

Postoperative pneumonia is a major complication in patients undergoing thoracic surgery. It leads to considerable morbidity and contributes to perioperative morbidity. There is evidence in literature that supports the use of strategies for improved oral hygiene and specialized endotracheal tubes in preventing ventilator associated pneumonia (VAP) in mechanically ventilated patients. This study aims at utilizing a combination of these interventions in the perioperative period in patients undergoing planned thoracic surgical procedures.

Ask AI to explain this study

Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studied0.12% chlorhexidine solution

The study team can explain what participation involves.

Who it may be forPost-operative Pneumonia · Lung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 8, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2 / Phase 3

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Washington University School of Medicine

Study sponsor

Study overview

What this study is about

Purpose: Prevention
Study type: Interventional
Phase: Phase 2 / Phase 3
Sponsor: Washington University School of Medicine
Interventions being studied: Drug: 0.12% chlorhexidine solution

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Study topics

After surgery (adjuvant)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Patients with lung lesions undergoing anatomic resection (lobectomy/segmentectomy/bilobectomy/pulmonary sleeve resection/pneumonectomy) 2. Patients with poor lung function (FEV1% \<50% or DLCO\<50% predicted or home oxygen requirement) and lung lesions undergoing non-anatomic lung resection (i.e. wedge resection). 3. Patients undergoing esophageal resection.

Reasons someone may not be able to joinExclusion criteria

1. Patients with ongoing symptomatic dental infections. 2. Patients with recent/ongoing pneumonia (\<15 days from initial surgical patient evaluation). 3. Patients who've received a therapeutic course of antibiotics within 15 days prior to thoracic surgery. 4. Patients with a preexisting tracheostomy. 5. Age\<18 6. Patients with an allergy to Peridex/chlorhexidine solution

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Washington University School of MedicineSt Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 8, 2018. Always confirm current availability with the study team.

View original record ↗